Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

umbilical cord blood-derived MAK immune cells

A preparation of mixed-activated killer (MAK) immune cells derived from human umbilical cord blood (UCB) cells, with potential cytotoxic activity. Hematopoietic stem cells (HSCs) are isolated followed by ex vivo differentiation and expansion. Upon administration, the UCB-derived MAK immune cells may lyse cancer cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	UCB-derived MAK cells UCB-derived MAK immune cells umbilical cord blood-derived mixed-activated killer immune cells

umbilical cord blood-derived MAK immune cells

Search NCI's Drug Dictionary